meglumine antimoniate has been researched along with Emesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esfandiarpour, I; Farajzadeh, S; Fathabadi, EA; Heshmatkhah, A; Rahnama, Z | 1 |
| Corzo, JE; de la Rosa, R; Delgado, J; González-Moreno, MP; Leal, M; Lissen, E; Macías, J; Pineda, JA; Sánchez-Quijano, A | 1 |
2 other study(ies) available for meglumine antimoniate and Emesis
| Article | Year |
|---|---|
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Antiprotozoal Agents; Child; Child, Preschool; Cross-Sectional Studies; Erythema; Female; Humans; Infant; Injections, Intralesional; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pain; Pruritus; Treatment Outcome; Vomiting; Young Adult | 2012 |
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Topics: Adult; Amylases; Animals; Antimony; Antiprotozoal Agents; Bone Marrow; Creatinine; Female; HIV Infections; HIV-1; Humans; Leishmania infantum; Leishmaniasis, Visceral; Leukocyte Count; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pancreatitis; Recurrence; Retrospective Studies; Vomiting | 1999 |